NCT07600788招募中1 期
A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.
Ausper Biopharma Co., Ltd.5 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2026年7月9日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 32
- 试验地点
- 5
研究概览
简要总结
A clinical study evaluating the pharmacokinetic characteristics and safety of AHB-137 injection in participants with mild to moderate liver dysfunction and those with normal liver function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Voluntarily participate in the study, sign an informed consent form before the study and be able to complete the study according to the requirements of the protocol;
- •At the time of signing the informed consent form, male or female participants aged 18-65 years (including threshold values);
- •Body mass index meets the criteria;
- •Take effective contraceptive measures as required;
- •Participants with liver function impairment need to meet certain liver function assessments;
- •Participants with normal liver function should meet certain age, weight, and gender requirements to match those with liver function impairment, and should also undergo certain physical and laboratory tests.
排除标准
- •Diagnosed or suspected liver cancer participants who have undergone liver transplantation;
- •History of vasculitis or presence of signs and symptoms of potential vasculitis or laboratory tests;
- •Unstable control of hypertension or diabetes, progressive nervous system disease, history of immune related extrahepatic diseases, and unstable cardiac function;
- •Participants with a history of malignant tumors or undergoing malignant tumor assessment;
- •Screening for participants who have undergone significant trauma or surgery within the previous 3 months, as well as those who plan to undergo surgery;
- •Participants with thyroid dysfunction who are not suitable for inclusion in the study;
- •Allergic or allergic constitution to AHB-137;
- •Long term regular receipt of anticoagulant or antiplatelet drugs is required;
- •Those who have received any antisense oligonucleotide drugs or have been treated with siRNA drugs or interferon within the 12 months prior to screening;
- •Currently using or using any immunosuppressive medication within the past 3 months prior to screening, except for short-term use or the use of topical/inhaled steroids; Individuals who have used immunomodulators and cytotoxic drugs within the 6 months prior to administration;
- •Those who have a history of vaccination or a plan to receive live vaccines within one month before administration, those who have used creatine containing fitness supplements 14 days before administration, and those who have used albumin 14 days before administration;
- •HIV, Syphilis positive ;
- •Those who are participating in another clinical trial and have not been eluted as required;
- •Positive results in urine drug screening and alcohol breath screening tests during screening;
- •Those who drink excessively and consume prohibited foods and beverages before administration;
- •Participants who have donated blood (or lost blood) ≥ 400 ml, received whole blood, or used red blood cell suspension within the past 3 months prior to screening; Individuals with a history of needle or blood dizziness, difficulty in blood collection, or intolerance to venipuncture blood collection;
- •Long term regular vigorous exercise or intense exercise within 48 hours before screening;
- •Any other circumstances or conditions that the researcher deems unsuitable for the subject to participate in this study;
- •Diseases that need to be excluded according to the merger plan for patients with abnormal liver function;
- •The laboratory test results do not meet the requirements of the protocol;
- •Participants with normal liver function who have a history of chronic liver disease or known liver or biliary abnormalities;
- •Participants with normal liver function who have used traditional Chinese medicine or other systemic medications with potential liver toxicity 14 days before administration;
- •Participants with normal liver function and abnormal QTcF values.
研究组 & 干预措施
Part1: Child-Pugh B group
Experimental
干预措施: AHB-137 injection (Drug)
Part2: Child-Pugh A group
Experimental
干预措施: AHB-137 injection (Drug)
Part1:Participants with normal liver function group
Experimental
干预措施: AHB-137 injection (Drug)
Part2:Participants with normal liver function group
Experimental
干预措施: AHB-137 injection (Drug)
研究者
研究点 (5)
Loading locations...
相似试验
进行中（未招募）
1 期
一项评估 AHB-137 注射液在轻度及中度肝功能损害参与者与肝功能正常参与者中的药代动力学特征及安全性临床研究慢性乙型肝炎CTR20261740杭州浩博医药有限公司
已完成
1 期
A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral ContraceptivesNCT07414784AbbVie20
Unknown
1 期
一项评价注射用 AAPB 用于中国健康受试者中的安全性、耐受性和药代动力学的剂量递增、随机、双盲、安慰剂对照、单次 / 多次给药Ⅰ期临床试验ChiCTR2400092269江苏康缘药业股份有限公司
已完成
1 期
一项评价注射用 AAPB 单次 / 多次给药Ⅰ期临床试验急性缺血性脑卒中CTR20243509江苏康缘药业股份有限公司 / 中国药科大学
进行中（未招募）
2 期
评估 AHB-137 注射液用于初治慢性乙型肝炎参与者的 II 期临床试验慢性乙型肝炎CTR20261990杭州浩博医药有限公司